LY 2969822

Drug Profile

LY 2969822

Alternative Names: LY-2969822

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 12 Dec 2013 Preclinical trials in Undefined indication in USA (PO)
  • 12 Dec 2013 Eli Lilly plans a phase I trial in Healthy volunteers in Singapore (NCT02018887)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top